ArticleTranslational cancer research2025
Integration of single-cell and bulk transcriptomics to explore prognostic and immunotherapeutic characteristics of sodium overload-induced cell death in lung adenocarcinoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent studies have identified a novel cell death mechanism, termed sodium death, triggered by sustained activation of Methods: This study conducted a comprehensive analysis of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases to investigate Results: Single-cell and bulk transcriptome analyses identified 126 NECSOs, of which 28 were differentially expressed between tumor and normal tissues. Among these, 14 genes were significantly associated with overall survival (OS). Pseudotime analysis of epithelial cells revealed that risk-associated genes were predominantly upregulated in later stages, whereas protective genes exhibited reduced expression over time. Eight genes were selected to construct a prognostic signature for NECSOs. Patients in the low-NECSOs group demonstrated significantly better prognosis compared to those in the high-NECSOs group. Cellular communication analysis indicated that epithelial cells with elevated NECSOs expression exhibited enhanced activity in the epidermal growth factor (EGF), Midkine (MK), and COMPLEMENT signaling pathways. Conclusions: The prognostic model developed from NECSOs enables robust survival prediction for LUAD patients and provides insights into the immune landscape of LUAD. Notably, epithelial cells with higher NECSOs scores displayed a greater propensity for transformation into tumor cells, highlighting their potential as therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.